Aspire Biopharma Provides Q3 2025 Business Update
ACCESS Newswire (Thu, 4-Dec 9:00 AM ET)
ACCESS Newswire (Tue, 2-Dec 9:00 AM ET)
Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member
ACCESS Newswire (Wed, 26-Nov 9:00 AM ET)
ACCESS Newswire (Thu, 6-Nov 9:00 AM ET)
ACCESS Newswire (Mon, 6-Oct 8:30 AM ET)
ACCESS Newswire (Fri, 3-Oct 11:30 AM ET)
Market Chameleon (Thu, 2-Oct 6:30 AM ET)
ACCESS Newswire (Wed, 1-Oct 8:30 AM ET)
ACCESS Newswire (Wed, 17-Sep 8:30 AM ET)
ACCESS Newswire (Tue, 16-Sep 8:30 AM ET)
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.
Aspire Biopharma Hldgs trades on the NASDAQ stock market under the symbol ASBP.
As of December 9, 2025, ASBP stock price was flat at $0.09 with 6,879,988 million shares trading.
ASBP has a beta of 3.41, meaning it tends to be more sensitive to market movements. ASBP has a correlation of 0.11 to the broad based SPY ETF.
ASBP has a market cap of $12.53 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that ASBP belongs to (by Net Assets): VXF.
ASBP support price is $.08 and resistance is $.10 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ASBP shares will trade within this expected range on the day.
